Pharmacological Treatment of Leprosy Based on National Guidelines
Multidrug therapy (MDT) regimens for different types of leprosy
Multidrug Therapy (MDT) is the standard treatment for leprosy, following WHO national guidelines to ensure effective disease management.
Pharmacological Treatment of Leprosy Based on National Guidelines
Introduction
Leprosy, caused by Mycobacterium leprae, is a chronic infectious disease primarily affecting the skin and peripheral nerves. The World Health Organization (WHO) has established Multidrug Therapy (MDT) regimens to effectively treat various types of leprosy.
MDT Regimens for Different Types of Leprosy
Paucibacillary (PB) Leprosy
- Duration: 6 months
- Drugs: Rifampicin (monthly), Dapsone (daily)
Multibacillary (MB) Leprosy
- Duration: 12 months
- Drugs: Rifampicin (monthly), Clofazimine (monthly & daily), Dapsone (daily)
Pharmacological Considerations
The MDT regimen is well-tolerated, but side effects such as hepatotoxicity (Rifampicin), hemolysis (Dapsone), and skin discoloration (Clofazimine) should be monitored. Adherence to national guidelines ensures the prevention of drug resistance.
Conclusion
MDT has significantly reduced leprosy prevalence globally. Early diagnosis and proper adherence to prescribed regimens are critical in eliminating the disease.
Tags
Recommended Reads
Explore related articles that might interest you
Pharmacological Treatment of Leprosy Based on National Guidelines
WHO Guidelines for the Treatment of Leprosy
Pharmacological Treatment of Leprosy Based on National Guidelines
WHO Guidelines for the Treatment of Leprosy
Clinical features, classification, and neurological examination of Leprosy
Clinical features, classification, and neurological examination of Leprosy
